Figure S2. Overview of the de-escalation rate to clopidogrel per participating community pharmacy

The de-escalation rate from ticagrelor/prasugrel to clopidogrel is shown per community pharmacy group (B trough H) and per independent community pharmacy (A). n^a denotes number of patients with a successful CYP2C19 test result, n^b number of patients eligible for de-escalation to clopidogrel (non- carriers of one or two CYP2C19*2 or *3 alleles).